LCM
CYTK icon

Leisure Capital Management’s Cytokinetics CYTK Stock Holding History

Leisure Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,067
Closed -$142K – 112
2017
Q1 		$142K Sell
11,067
-301
-3% -$3.52K 0.13% 97
2016
Q4 		$138K Buy
11,368
+215
+2% +$2.28K 0.12% 98
2016
Q3 		$102K Sell
11,153
-61
-0.5% -$637 0.1% 97
2016
Q2 		$106K Buy
11,214
+14
+0.1% +$115 0.1% 99
2016
Q1 		$79K Buy
+11,200
New +$81.8K 0.08% 99
2015
Q4 		– Sell
-12,167
Closed -$81K – 110
2015
Q3 		$81K Sell
12,167
-5,400
-31% -$36.9K 0.09% 93
2015
Q2 		$118K Buy
17,567
+1,055
+6% +$6.92K 0.12% 90
2015
Q1 		$112K Buy
16,512
+1,086
+7% +$8.11K 0.11% 92
2014
Q4 		$124K Buy
+15,426
New +$66.2K 0.12% 90

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Leisure Capital Management's CYTK Position: Q2 2017 in Review

Leisure Capital Management sold out of Cytokinetics (CYTK) in Q2 2017, closing a stake of 11,067 shares — an estimated $142K sold.

Leisure Capital Management first reported a position in CYTK in Q4 2014 and held it in 9 quarters. The position peaked at $142K in Q1 2017. 136 funds tracked by Wall St. Rank hold CYTK as of Q2 2017.

  • Leisure Capital Management reported no remaining Cytokinetics position as of Q2 2017 after selling out during the quarter.
  • Leisure Capital Management sold 11,067 Cytokinetics shares in Q2 2017, an estimated $142K.
  • Leisure Capital Management first reported a position in Cytokinetics in Q4 2014 and held it in 9 quarters.
  • Leisure Capital Management's Cytokinetics position peaked at $142K in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2017.

Based on Leisure Capital Management's 13F filing for Q2 2017, filed 9 Aug 2017.